Selected research
Industry Research
Peptide CDMO Industry Research Report 2026
Market perspective
The global Peptide CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Peptide CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Peptide CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Peptide CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Peptide CDMO include Xinbang Pharma, ScinoPharm, SN Biopharm, Genscript, AmbioPharm, USV Peptides, Thermofischer, PolyPeptide and Piramal Pharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Peptide CDMO market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Peptide CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide CDMO Market by Company
Xinbang Pharma
ScinoPharm
SN Biopharm
Genscript
AmbioPharm
USV Peptides
Thermofischer
PolyPeptide
Piramal Pharma
JPT
CPC Scientific
CordenPharma
CBL
Bio Basic
Bachem
Peptide CDMO Segment by Type
APIs and Intermediates
FDF
Peptide CDMO Segment by Application
Commercial
Academic Research
Other
Peptide CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Peptide CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- APIs and Intermediates
- FDF
Applications
- Commercial
- Academic Research
- Other
Companies covered
- Xinbang Pharma
- ScinoPharm
- SN Biopharm
- Genscript
- AmbioPharm
- USV Peptides
- Thermofischer
- PolyPeptide
- Piramal Pharma
- JPT
- CPC Scientific
- CordenPharma
- CBL
- Bio Basic
- Bachem
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Peptide CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 APIs and Intermediates
- 2.2.3 FDF
- 2.3 Peptide CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Commercial
- 2.3.3 Academic Research
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Peptide CDMO Breakdown Data by Type
- 3.1 Global Peptide CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Peptide CDMO Forecasted Market Size by Type (2027-2032)
4 Peptide CDMO Breakdown Data by Application
- 4.1 Global Peptide CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Peptide CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Peptide CDMO Market Perspective (2021-2032)
- 5.2 Global Peptide CDMO Growth Trends by Region
- 5.2.1 Global Peptide CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Peptide CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Peptide CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Peptide CDMO Market Dynamics
- 5.3.1 Peptide CDMO Industry Trends
- 5.3.2 Peptide CDMO Market Drivers
- 5.3.3 Peptide CDMO Market Challenges
- 5.3.4 Peptide CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Peptide CDMO Players by Revenue
- 6.1.1 Global Top Peptide CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Peptide CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Peptide CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Peptide CDMO Head Office and Area Served
- 6.4 Global Peptide CDMO Players, Product Type & Application
- 6.5 Global Peptide CDMO Manufacturers Established Date
- 6.6 Global Peptide CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Peptide CDMO Market Size (2021-2032)
- 7.2 North America Peptide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Peptide CDMO Market Size by Country (2021-2026)
- 7.4 North America Peptide CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Peptide CDMO Market Size (2021-2032)
- 8.2 Europe Peptide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Peptide CDMO Market Size by Country (2021-2026)
- 8.4 Europe Peptide CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Peptide CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Peptide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Peptide CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Peptide CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Peptide CDMO Market Size (2021-2032)
- 10.2 South America Peptide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Peptide CDMO Market Size by Country (2021-2026)
- 10.4 South America Peptide CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Peptide CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Peptide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Peptide CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Peptide CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Xinbang Pharma
- 12.1.1 Xinbang Pharma Company Information
- 12.1.2 Xinbang Pharma Business Overview
- 12.1.3 Xinbang Pharma Revenue in Peptide CDMO Business (2021-2026)
- 12.1.4 Xinbang Pharma Peptide CDMO Product Portfolio
- 12.1.5 Xinbang Pharma Recent Developments
- 12.2 ScinoPharm
- 12.2.1 ScinoPharm Company Information
- 12.2.2 ScinoPharm Business Overview
- 12.2.3 ScinoPharm Revenue in Peptide CDMO Business (2021-2026)
- 12.2.4 ScinoPharm Peptide CDMO Product Portfolio
- 12.2.5 ScinoPharm Recent Developments
- 12.3 SN Biopharm
- 12.3.1 SN Biopharm Company Information
- 12.3.2 SN Biopharm Business Overview
- 12.3.3 SN Biopharm Revenue in Peptide CDMO Business (2021-2026)
- 12.3.4 SN Biopharm Peptide CDMO Product Portfolio
- 12.3.5 SN Biopharm Recent Developments
- 12.4 Genscript
- 12.4.1 Genscript Company Information
- 12.4.2 Genscript Business Overview
- 12.4.3 Genscript Revenue in Peptide CDMO Business (2021-2026)
- 12.4.4 Genscript Peptide CDMO Product Portfolio
- 12.4.5 Genscript Recent Developments
- 12.5 AmbioPharm
- 12.5.1 AmbioPharm Company Information
- 12.5.2 AmbioPharm Business Overview
- 12.5.3 AmbioPharm Revenue in Peptide CDMO Business (2021-2026)
- 12.5.4 AmbioPharm Peptide CDMO Product Portfolio
- 12.5.5 AmbioPharm Recent Developments
- 12.6 USV Peptides
- 12.6.1 USV Peptides Company Information
- 12.6.2 USV Peptides Business Overview
- 12.6.3 USV Peptides Revenue in Peptide CDMO Business (2021-2026)
- 12.6.4 USV Peptides Peptide CDMO Product Portfolio
- 12.6.5 USV Peptides Recent Developments
- 12.7 Thermofischer
- 12.7.1 Thermofischer Company Information
- 12.7.2 Thermofischer Business Overview
- 12.7.3 Thermofischer Revenue in Peptide CDMO Business (2021-2026)
- 12.7.4 Thermofischer Peptide CDMO Product Portfolio
- 12.7.5 Thermofischer Recent Developments
- 12.8 PolyPeptide
- 12.8.1 PolyPeptide Company Information
- 12.8.2 PolyPeptide Business Overview
- 12.8.3 PolyPeptide Revenue in Peptide CDMO Business (2021-2026)
- 12.8.4 PolyPeptide Peptide CDMO Product Portfolio
- 12.8.5 PolyPeptide Recent Developments
- 12.9 Piramal Pharma
- 12.9.1 Piramal Pharma Company Information
- 12.9.2 Piramal Pharma Business Overview
- 12.9.3 Piramal Pharma Revenue in Peptide CDMO Business (2021-2026)
- 12.9.4 Piramal Pharma Peptide CDMO Product Portfolio
- 12.9.5 Piramal Pharma Recent Developments
- 12.10 JPT
- 12.10.1 JPT Company Information
- 12.10.2 JPT Business Overview
- 12.10.3 JPT Revenue in Peptide CDMO Business (2021-2026)
- 12.10.4 JPT Peptide CDMO Product Portfolio
- 12.10.5 JPT Recent Developments
- 12.11 CPC Scientific
- 12.11.1 CPC Scientific Company Information
- 12.11.2 CPC Scientific Business Overview
- 12.11.3 CPC Scientific Revenue in Peptide CDMO Business (2021-2026)
- 12.11.4 CPC Scientific Peptide CDMO Product Portfolio
- 12.11.5 CPC Scientific Recent Developments
- 12.12 CordenPharma
- 12.12.1 CordenPharma Company Information
- 12.12.2 CordenPharma Business Overview
- 12.12.3 CordenPharma Revenue in Peptide CDMO Business (2021-2026)
- 12.12.4 CordenPharma Peptide CDMO Product Portfolio
- 12.12.5 CordenPharma Recent Developments
- 12.13 CBL
- 12.13.1 CBL Company Information
- 12.13.2 CBL Business Overview
- 12.13.3 CBL Revenue in Peptide CDMO Business (2021-2026)
- 12.13.4 CBL Peptide CDMO Product Portfolio
- 12.13.5 CBL Recent Developments
- 12.14 Bio Basic
- 12.14.1 Bio Basic Company Information
- 12.14.2 Bio Basic Business Overview
- 12.14.3 Bio Basic Revenue in Peptide CDMO Business (2021-2026)
- 12.14.4 Bio Basic Peptide CDMO Product Portfolio
- 12.14.5 Bio Basic Recent Developments
- 12.15 Bachem
- 12.15.1 Bachem Company Information
- 12.15.2 Bachem Business Overview
- 12.15.3 Bachem Revenue in Peptide CDMO Business (2021-2026)
- 12.15.4 Bachem Peptide CDMO Product Portfolio
- 12.15.5 Bachem Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst